HB951 would repeal and replace Missouri’s existing section 191.480 on investigational treatments and add a new section 191.479 creating a limited legal framework for the therapeutic use of psilocybin. The bill would allow adults age 21 and older to acquire, use, possess, transfer, or administer psilocybin for their own therapeutic use without violating state or local law, so long as they meet specified conditions. Those conditions include having a qualifying condition such as end-of-life care needs, PTSD, major depressive disorder, substance use disorder, or another condition for which psilocybin has shown efficacy in FDA-registered clinical trials; obtaining documentation from a physician or certified nurse practitioner in a bona fide prescriber-patient relationship; identifying a qualified facilitator; using a state-tested product; and staying within a 150-milligram annual limit.
The bill also establishes training and qualification standards for facilitators who would be present during psilocybin use, including psilocybin-specific training approved for continuing education credit by the American Psychological Association and additional training in relevant mental health and end-of-life conditions. It further protects facilitators, laboratories, physicians, nurse practitioners, and other health care providers from state criminal, civil, and licensing consequences for participating in the bill’s authorized activities, except in cases of gross negligence or willful misconduct. The Department of Mental Health would collect certain information, maintain confidentiality of personally identifiable protected information, and be prohibited from disclosing the statewide list or individual information to federal authorities or unauthorized third parties.
HB951 would also revise the state’s “right-to-try” style investigational treatment law in section 191.480. The amended section would define eligible patients and investigational drugs, require manufacturer registration with the Department of Health and Senior Services, and create a registry for manufacturers of investigational products involving controlled substances by November 1, 2025. It would preserve the rule that insurers and the Department of Corrections are not required to cover investigational treatments, while continuing to protect physicians and providers from licensure or certification consequences for recommending such treatments to eligible patients.
The bill’s impact on state law would be significant because it creates a new state-level exception to existing controlled-substance prohibitions for psilocybin used in a tightly regulated therapeutic context, while also expanding legal protections for medical professionals and laboratories involved in that use. It would require the Department of Mental Health and the Department of Health and Senior Services to administer new confidentiality and registry functions, and it would limit state enforcement against authorized therapeutic psilocybin activity. At the same time, it would leave federal law unchanged and does not appear to alter insurance coverage mandates.
No committee transcript or vote history was provided, so the overall sentiment cannot be measured from recorded debate or roll calls. Based on the bill’s structure, it appears designed to support access to psychedelic-assisted therapy for serious mental health and end-of-life conditions while imposing guardrails around patient eligibility, provider qualifications, and product testing. The main likely points of contention are the legalization of psilocybin under state law, the scope of qualifying conditions, the adequacy of training and oversight for facilitators, confidentiality and information-sharing restrictions, and the extent of liability protections for providers and laboratories.
HB951 would repeal and replace Missouri’s current investigational-treatment statute and create a new psilocybin therapeutic-use exemption from state and local controlled-substance laws for qualifying adults. It would also impose new duties on the Department of Mental Health and the Department of Health and Senior Services, including confidentiality protections and a manufacturer registry for investigational products involving controlled substances. Physicians, nurse practitioners, facilitators, and testing laboratories would receive broad immunity from state civil, criminal, and licensing consequences for conduct authorized by the bill, while the existing right-to-try framework for investigational drugs and devices would be updated and retained in modified form.
No votes or committee discussion were provided, so there is no recorded legislative sentiment to summarize from debate or roll-call data. The bill’s text suggests a policy goal of expanding therapeutic access to psilocybin and investigational treatments for serious illnesses, with a cautious, regulated approach rather than unrestricted access. The absence of recorded opposition or support in the provided materials means sentiment cannot be assessed beyond the bill’s apparent pro-access orientation.
The most likely areas of contention are the bill’s authorization of psilocybin use despite existing controlled-substance restrictions, the breadth of conditions that qualify for use, and whether the proposed training and facilitator requirements are sufficient to ensure patient safety. Additional concerns may include the confidentiality and non-disclosure provisions limiting state sharing of participant information, the liability shields for providers and laboratories, and the practical interaction between the bill’s state protections and federal controlled-substance law. Supporters would likely emphasize treatment access for end-of-life care, PTSD, depression, and substance use disorders, while critics may focus on public-health, regulatory, and enforcement concerns.